Authors
Latest:
Immune Checkpoint Inhibitors Revolutionize Endometrial Cancer TreatmentThe incorporation of immune checkpoint inhibitors has altered the treatment paradigm for endometrial cancer.
Latest:
Overcoming Hurdles to Biosimilar UptakeSanjiv S. Agarwala, MD, explains that biologics have revolutionized the treatment of serious conditions, including cancer, over the past few decades, however, costs are a pressing issue for all providers and biologics are a major culprit.
Latest:
Dr. Federico on Risk Categorization in NeuroblastomaSara M. Federico, MD, discusses risk categorization in neuroblastoma.
Latest:
Dr. Aguirre-Ghiso on Future Research Directions at Albert Einstein Cancer CenterJulio Aguirre-Ghiso, PhD, discusses future research directions being conducted by investigators at the Albert Einstein Cancer Center.
Latest:
Dr. Bechara on Minimally Invasive Bronchoscopic Approaches in Lung CancerRabih I. Bechara, MD, FCCP, discusses how minimally invasive bronchoscopic approaches are utilized in lung cancer.
Latest:
Dr Brastianos Breaks Down the Basics of MeningiomasPriscilla K. Brastianos, MD, explains the differences between low-grade meningiomas and aggressive high-grade tumors.
Latest:
Dr. Walden on the RNA Expression of Homologous Recombination Genes in CRCDaniel Walden, MD, discusses the association of low expression of RNA of wild-type homologous recombination genes and survival in colorectal cancer.
Latest:
Dr. Chedid on Understanding Treatment Efficacy in Follicular LymphomaSolly Chedid, MD, discusses the elements of effective therapy in follicular lymphoma.
Latest:
Dr. Price on the Rationale for Sotorasib in Advanced Gastrointestinal CancersTimothy Price, MBBS, DHthSc, FRACP, discusses the rationale to evaluate sotorasib in gastrointestinal cancers.
Latest:
Dr Kyriakopoulos on the Initial Activity and Safety of Masofaniten Plus Enzalutamide in mCRPCChristos Kyriakopoulos, MD, discusses data from a phase 1/2 study of masofaniten plus enzalutamide in metastatic castration-resistant prostate cancer.
Latest:
Dr. Castaneda Puglianini on Next Steps With CAR T-Cell Therapy in Multiple MyelomaOmar Castaneda Puglianini, MD, hematologist and medical oncologist, Moffitt Cancer Center, discusses next steps with CAR T-cell therapy in penta-refractory multiple myeloma.
Latest:
Dr. Hurley on Breast Cancer Baseline Characteristics in the Caribbean Vs the United StatesJudith E. Hurley, MD, discusses the baseline characteristics of patients with breast cancer in the Caribbean vs those in the United States.
Latest:
Dr. Susanibar on Important Considerations When Treating Multiple MyelomaSandra P. Susanibar-Adaniya, MD, discusses important considerations when treating patients with multiple myeloma.
Latest:
Dr. Thomas on the Rationale for the Phase 2 DDRiver SCLC 250 Trial in SCLCAnish Thomas, MBBS, MD, medical oncologist, Lasker Clinical Research Scholar, Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, discusses the rationale for the phase 2 DDRiver SCLC 250 trial in relapsed, platinum-resistant small cell lung cancer.
Latest:
Exploring High-Intensity Focused Ultrasound as an Organ-Sparing Option for Prostate CancerThe definitive treatment of prostate cancer has historically relied on whole-gland treatment.
Latest:
Dr Negrao on JDQ443 Plus TNO155 in Advanced, KRAS G12C–Mutated Solid TumorsMarcelo Vailati Negrao, MD, discusses efficacy findings from the phase 1b/2 KontRASt-01 trial (NCT04699188) in patients with KRAS G12C–mutated solid tumors.
Latest:
Dr Soliman on the Use of ctDNA as a Clinical Trial End Point in Endometrial CancerPamela T. Soliman, MD, MPH, discusses the use of circulating tumor DNA a clinical trial end point in endometrial cancer.
Latest:
Sarcoma, the “Forgotten Cancer”: Examining What’s Needed to Improve CareSarcomas, all together, have an incidence of less than 5/100,000 persons per year, according to the Surveillance, Epidemiology, and End Results Program. Compare that with breast cancer, which impacts 129.1/100,000 women per year, or lung cancer, which has an incidence of 53.1/100,000 persons per year
Latest:
Adjuvant Mitotane Fails to Improve RFS in Patients with ACC at Low/Intermediate Risk of RecurrenceThe utilization of mitotane in the adjuvant setting did not produce significant benefit for patients with adrenocortical carcinoma at low or intermediate risk of recurrence.
Latest:
Location Matters: US Patients With Adult T-Cell Leukemia/Lymphoma Have Distinct Clinical, Genetic FeaturesAdult T-cell leukemia/lymphoma is a rare and very aggressive T-cell neoplasm with an extremely poor prognosis. It is also the only human cancer caused by a retrovirus—human T-cell leukemia virus.
Latest:
Novel Treatment Approaches for SCLC and Future PerspectivesA panel of expert oncologists offer closing thoughts on the future treatment landscape and unmet needs in small-cell lung cancer.
Latest:
Rutgers Cancer Institute of New Jersey and RWJBarnabas Health Retains its Position as New Jersey’s Only National Cancer Institute-Designated Comprehensive Cancer CenterRutgers Cancer Institute of New Jersey along with RWJBarnabas Health was redesignated by the National Cancer Institute.
Latest:
Relapsed/Refractory Follicular Lymphoma: Future Directions in CareKey opinion leaders Sameh Gaballa, MD, and Matthew Lunning, DO, FACP, consider the evolving treatment landscape of follicular lymphoma and look toward future evolutions in the field.
Latest:
Dr Aldoss on the Use of Revumenib in KMT2A-Rearranged Acute LeukemiaIbrahim T. Aldoss, MD, discusses the use of revumenib monotherapy in patients with relapsed/refractory acute leukemia harboring KMT2A rearrangements.
Latest:
Dr Velázquez Mañana on Survivorship Care Needs in Older Patients With Lung CancerAna Velázquez Mañana, MD, discusses findings from a study determining survivorship care needs in low-income, older patients with lung cancer.
Latest:
Updated Overall Survival from the Phase 3 TOPAZ-1 Study of Durvalumab or Placebo plus Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract CancerDo-Youn Oh, MD reviews the updated OS results of the phase 3 study, TOPAZ-1, evaluating the use of durvalumab plus GemCis versus placebo for patients with advanced biliary tract cancer (BTC).
Latest:
Let’s Talk About Post-Mastectomy Chest NumbnessJust as advances in surgical techniques have made it possible to treat breast cancer and offer numerous options for breast reconstruction, there is also a surgical advancement to address a functional impairment often unintentionally caused by mastectomy: chest numbness.
Latest:
Dr Bodor on a Study Profiling Estrogen Species in Women With EGFR-Mutated NSCLCJ. Nicholas Bodor, MD, PhD, MPH, discusses the results of prior research supporting the inception of a study that profiled reactive estrogen species in women with EGFR-positive non–small cell lung cancer, as well as the findings from this study.
